These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2246703)

  • 1. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neurotrauma on hepatic drug clearance.
    Boucher BA; Kuhl DA; Fabian TC; Robertson JT
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):487-97. PubMed ID: 1934861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver volume as a determinant of drug clearance in children and adolescents.
    Murry DJ; Crom WR; Reddick WE; Bhargava R; Evans WE
    Drug Metab Dispos; 1995 Oct; 23(10):1110-6. PubMed ID: 8654200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.
    Crom WR; Relling MV; Christensen ML; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1991 Aug; 50(2):132-40. PubMed ID: 1868674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous administration of multiple model substrates to assess hepatic drug clearance.
    Crom WR; Webster SL; Bobo L; Teresi ME; Relling MV; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):645-50. PubMed ID: 3581648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
    Andersen V; Sonne J; Larsen S
    Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy.
    Relling MV; Crom WR; Pieper JA; Cupit GC; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):651-60. PubMed ID: 3472701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of experimental hemorrhagic shock on hepatic drug elimination.
    DiPiro JT; Hooker KD; Sherman JC; Gaines MG; Wynn JJ
    Crit Care Med; 1992 Jun; 20(6):810-5. PubMed ID: 1597036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment.
    Andersen V; Sonne J; Court-Payen M; Sletting S; Prip A; Mølholm Hansen J
    Scand J Gastroenterol; 1999 Jun; 34(6):618-22. PubMed ID: 10440613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers.
    Klockowski PM; Lener ME; Sirgo MA; Rocci ML
    Clin Pharmacol Ther; 1990 Oct; 48(4):375-80. PubMed ID: 2146057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
    Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
    Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of isolated hepatic ischemia on organic anion clearance and oxidative metabolism.
    Minard G; Bynoe R; Wood GC; Fabian TC; Croce M; Kudsk KA
    J Trauma; 1992 Apr; 32(4):514-8; discussion 518-9. PubMed ID: 1569625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice.
    Kulkarni SG; Pegram AA; Smith PC
    AAPS PharmSci; 2000; 2(2):E18. PubMed ID: 11741234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
    Eldon MA; Luecker PW; MacGee J; Ritschel WA
    J Clin Pharmacol; 1987 Mar; 27(3):226-32. PubMed ID: 3680579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
    Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
    Adams MH; Poynor WJ; Garnett WR; Karnes HT; Ferry JJ; Ryan KK; Sarkar MA
    Biopharm Drug Dispos; 1998 Nov; 19(8):501-15. PubMed ID: 9840212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig.
    Monshouwer M; Witkamp RF; Nijmeijer SM; Pijpers A; Verheijden JH; Van Miert AS
    Xenobiotica; 1995 May; 25(5):491-9. PubMed ID: 7571722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S; Rowinsky E; Slichenmyer W; Donehower RC; Forastiere A; Ettinger D; Chen TL; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow LB
    J Natl Cancer Inst; 1996 Jun; 88(12):817-24. PubMed ID: 8637048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.